Short answer
aTYR PHARMA INC (ATYR) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $190,000 with net income of −$26M.
Q3 2025 key financials · XBRL
- Revenue
- $190,000
- Net income
- −$26M
- −49.2% YoY · −31.8% QoQ
- Operating margin
- -14076.3%
- EPS (diluted)
- −$0.27
- −17.4% YoY · −22.7% QoQ
Source: XBRL data from the aTYR PHARMA INC (ATYR) Q3 2025 10-Q on SEC EDGAR. USD.
aTYR PHARMA INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- EFZO-FIT primary-endpoint failure in September 2025, triggering FDA review and potential additional trials for pulmonary sarcoidosis
- No established FDA approval pathway for pulmonary sarcoidosis, with endpoint uncertainty undermining efzofitimod approvability
- CDMO process-performance failure in Q1 2025, requiring replacement of the first upstream batch
- Limited SSc-ILD enrollment pool, with up to 80% of approximately 100,000 U.S. systemic-sclerosis patients potentially developing ILD
- Foreign clinical-trial exposure, including FDA rejection risk for non-U.S. data and foreign-exchange fluctuations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other aTYR PHARMA INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.